Imscin002 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Imscin002 . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Imscin002 Today - Breaking & Trending Today

Phase 2 IMscin002 Study Shows Patients With NSCLC Prefer Subcutaneous Atezolizumab

Published: March 23, 2024

Patients with non–small cell lung cancer treated on the IMscin002 trial preferred subcutaneous atezolizumab vs the intravenous formulation.

Source: onclive.com

Related Topics:

Federico CappuzzoEli LillyEuropean Lung Cancer CongressEuropean CommissionBristol Myers SquibbIllumina IncMirati Therapeutics IncBayer AgRoche LtdTakeda PharmaceuticalsAmgen IncLung CancerMedical OncologyAzienda UnitSanitaria LocaleMirati TherapeuticsGalecto BiotechImscin002 Non Small Cell Lung CancerSubcutaneous AtezolizumabIntravenous AtezolizumabPhase 2 Imscin002 Trial Azienda Unità Sanitaria Locale Della Romagna Ravenna